vs

Side-by-side financial comparison of HARTE HANKS INC (HHS) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.

HARTE HANKS INC is the larger business by last-quarter revenue ($39.9M vs $37.2M, roughly 1.1× Organogenesis Holdings Inc.). On growth, HARTE HANKS INC posted the faster year-over-year revenue change (-15.4% vs -57.1%). Over the past eight quarters, HARTE HANKS INC's revenue compounded faster (-6.4% CAGR vs -46.5%).

Harte Hanks is a global marketing services company headquartered in Boston, Massachusetts. Harte Hanks services include analytics, strategy, marketing technology, creative services, digital marketing, customer care, direct mail, logistics, and fulfillment.

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

HHS vs ORGO — Head-to-Head

Bigger by revenue
HHS
HHS
1.1× larger
HHS
$39.9M
$37.2M
ORGO
Growing faster (revenue YoY)
HHS
HHS
+41.6% gap
HHS
-15.4%
-57.1%
ORGO
Faster 2-yr revenue CAGR
HHS
HHS
Annualised
HHS
-6.4%
-46.5%
ORGO

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
HHS
HHS
ORGO
ORGO
Revenue
$39.9M
$37.2M
Net Profit
$2.2M
Gross Margin
30.8%
Operating Margin
-0.3%
-185.1%
Net Margin
5.5%
Revenue YoY
-15.4%
-57.1%
Net Profit YoY
EPS (diluted)
$0.30

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HHS
HHS
ORGO
ORGO
Q1 26
$37.2M
Q4 25
$39.9M
$225.6M
Q3 25
$39.5M
$150.9M
Q2 25
$38.6M
$101.0M
Q1 25
$41.6M
$86.7M
Q4 24
$47.1M
$126.7M
Q3 24
$47.6M
$115.2M
Q2 24
$45.0M
$130.2M
Net Profit
HHS
HHS
ORGO
ORGO
Q1 26
Q4 25
$2.2M
$43.7M
Q3 25
$-2.3M
$21.6M
Q2 25
$-335.0K
$-9.4M
Q1 25
$-392.0K
$-18.8M
Q4 24
$7.7M
Q3 24
$142.0K
$12.3M
Q2 24
$-27.8M
$-17.0M
Gross Margin
HHS
HHS
ORGO
ORGO
Q1 26
30.8%
Q4 25
Q3 25
Q2 25
Q1 25
72.6%
Q4 24
75.5%
Q3 24
76.7%
Q2 24
77.6%
Operating Margin
HHS
HHS
ORGO
ORGO
Q1 26
-185.1%
Q4 25
-0.3%
28.1%
Q3 25
1.3%
13.7%
Q2 25
0.1%
-12.5%
Q1 25
-0.1%
-30.9%
Q4 24
-3.3%
8.1%
Q3 24
4.0%
5.4%
Q2 24
3.0%
-10.7%
Net Margin
HHS
HHS
ORGO
ORGO
Q1 26
Q4 25
5.5%
19.4%
Q3 25
-5.8%
14.3%
Q2 25
-0.9%
-9.3%
Q1 25
-0.9%
-21.7%
Q4 24
6.1%
Q3 24
0.3%
10.7%
Q2 24
-61.8%
-13.1%
EPS (diluted)
HHS
HHS
ORGO
ORGO
Q1 26
Q4 25
$0.30
$0.31
Q3 25
$-0.31
$0.11
Q2 25
$-0.05
$-0.10
Q1 25
$-0.05
$-0.17
Q4 24
$-0.31
$0.05
Q3 24
$0.02
$0.09
Q2 24
$-3.84
$-0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HHS
HHS
ORGO
ORGO
Cash + ST InvestmentsLiquidity on hand
$5.6M
$91.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$20.5M
Total Assets
$91.8M
$520.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HHS
HHS
ORGO
ORGO
Q1 26
$91.4M
Q4 25
$5.6M
$93.7M
Q3 25
$6.5M
$63.7M
Q2 25
$4.8M
$73.1M
Q1 25
$9.0M
$110.0M
Q4 24
$9.8M
$135.6M
Q3 24
$5.9M
$94.3M
Q2 24
$11.0M
$89.9M
Total Debt
HHS
HHS
ORGO
ORGO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$62.3M
Q2 24
$63.8M
Stockholders' Equity
HHS
HHS
ORGO
ORGO
Q1 26
Q4 25
$20.5M
$300.1M
Q3 25
$19.9M
$255.1M
Q2 25
$22.2M
$233.2M
Q1 25
$21.4M
$242.9M
Q4 24
$21.7M
$262.9M
Q3 24
$21.0M
$278.5M
Q2 24
$20.6M
$263.5M
Total Assets
HHS
HHS
ORGO
ORGO
Q1 26
$520.0M
Q4 25
$91.8M
$598.7M
Q3 25
$92.7M
$509.8M
Q2 25
$95.0M
$461.1M
Q1 25
$100.6M
$467.4M
Q4 24
$101.8M
$497.9M
Q3 24
$108.1M
$446.3M
Q2 24
$109.7M
$443.2M
Debt / Equity
HHS
HHS
ORGO
ORGO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.22×
Q2 24
0.24×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HHS
HHS
ORGO
ORGO
Operating Cash FlowLast quarter
$737.0K
Free Cash FlowOCF − Capex
$-686.0K
FCF MarginFCF / Revenue
-1.7%
Capex IntensityCapex / Revenue
3.6%
Cash ConversionOCF / Net Profit
0.33×
TTM Free Cash FlowTrailing 4 quarters
$-4.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HHS
HHS
ORGO
ORGO
Q1 26
Q4 25
$737.0K
$39.4M
Q3 25
$3.2M
$3.1M
Q2 25
$-4.8M
$-32.9M
Q1 25
$-818.0K
$-19.9M
Q4 24
$4.0M
$10.9M
Q3 24
$-2.9M
$8.7M
Q2 24
$1.6M
$4.7M
Free Cash Flow
HHS
HHS
ORGO
ORGO
Q1 26
Q4 25
$-686.0K
$34.8M
Q3 25
$2.2M
$844.0K
Q2 25
$-5.1M
$-36.5M
Q1 25
$-923.0K
$-23.6M
Q4 24
$3.4M
$7.6M
Q3 24
$-4.9M
$6.1M
Q2 24
$926.0K
$2.9M
FCF Margin
HHS
HHS
ORGO
ORGO
Q1 26
Q4 25
-1.7%
15.4%
Q3 25
5.5%
0.6%
Q2 25
-13.1%
-36.1%
Q1 25
-2.2%
-27.2%
Q4 24
7.3%
6.0%
Q3 24
-10.2%
5.3%
Q2 24
2.1%
2.2%
Capex Intensity
HHS
HHS
ORGO
ORGO
Q1 26
Q4 25
3.6%
2.1%
Q3 25
2.5%
1.5%
Q2 25
0.6%
3.6%
Q1 25
0.3%
4.2%
Q4 24
1.3%
2.7%
Q3 24
4.0%
2.2%
Q2 24
1.5%
1.4%
Cash Conversion
HHS
HHS
ORGO
ORGO
Q1 26
Q4 25
0.33×
0.90×
Q3 25
0.14×
Q2 25
Q1 25
Q4 24
1.43×
Q3 24
-20.76×
0.71×
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HHS
HHS

Fulfillment And Logistics Services$17.3M43%
Customer Care$13.7M34%
Other$8.9M22%

ORGO
ORGO

Segment breakdown not available.

Related Comparisons